Germany's Askion to manufacture Electro-Optical Sciences (EOS) MelaFind for US clinical trials:
This article was originally published in Clinica
Electro-Optical Sciences (EOS), an Irvington, New York-based developer of noninvasive, point-of-care devices for early diagnosis of melanoma, has appointed Askion, of Gera, Germany, as manufacturer of its hand-held imaging product MelaFind. The device will undergo clinical trials in the US to establish its safety and efficacy in the imaging of suspicious skin lesions. Data from the trials will be submitted in support of a US premarket approval, which EOS expects to receive in 2007. Financial terms of the agreement were not disclosed. Melanomas are responsible for 80% of all skin cancer deaths. Early diagnosis is essential to ensure good survival rates as there is no cure for advanced stage melanoma.
You may also be interested in...
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
Results of a forthcoming APhA survey showed about one-third cannot store Pfizer/BioNTech's BNT162b2, but can handle Moderna's mRNA-1273.